SUBSCRIBE
SUBSCRIBE
News   Drug Development

Unique Structure Of Geron Corporation’s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity In Lung Cancer Cells

February 15, 2007 | 
1 min read
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti-tumor and anti-metastatic activity.
Preclinical
MORE ON THIS TOPIC
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Cardiovascular disease
Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
September 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
When vision fades: Rethinking wet AMD and the durability gap
September 17, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
ALS
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
September 16, 2026
 · 
2 min read
 · 
Heather McKenzie
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
 · 
1 min read
 · 
Jef Akst